Cidara Therapeutics (CDTX) Misses Q1 EPS by 221c

Cidara Therapeutics (NASDAQ: CDTX) reported Q1 EPS of ($2.28), $2.21 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $8.46 million versus the consensus estimate of $13.05 million.

For earnings history and earnings-related data on Cidara Therapeutics (CDTX) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Ennis (EBF) Reports In-Line Q1 EPS
• Morgan Stanley sees little room left in steel rally, cuts Cleveland-Cliffs rating